Penpulimab-kcqx: FDA-Approved PD-1 Inhibitor for non-keratinizing  Nasopharyngeal Carcinoma

Name of Drug : Penpulimab-kcqx Drug Category : Antineoplastic agent Form : Injection . Introduction : Nasopharyngeal carcinoma (NPC) is a rare cancer that arises in the nasopharynx, most often seen in the non-keratinizing form linked to the Epstein Barr virus. In April 2025, the FDA approved a promising immunotherapy: penpulimab KCQX, a next-generation PD1 …

Read more

Acoltremon Ophthalmic Solution 0.003 for Dry Eye Disease: A New Breakthrough in Ocular Therapy

Generic Name : Acoltremon Brand Name :Tryptyr Drug Class : TRPM8 thermoreceptor agonist Dosage : Ophthalmic Solution 0.003 Introduction: Dry eye disease (DED) affects millions of people worldwide, causing discomfort, blurred vision, and irritation that can impact daily life. Conventional treatments such as artificial tears or steroids often provide temporary relief. Enter acoltremone – a …

Read more

Avmapki Fakzynja

🌿 Avmapki Fakzynja Co-Pack: FDA-Approved Breakthrough for KRAS-Mutated Ovarian Cancer

Brand Name : Avmapki Fakzynja Co-pack Generic Name : avutometinib and defactinib Dosage form :Avmapki capsules , Fakzynja tablets . 🔹 Introduction : Ovarian cancer is one of the most challenging gynecologic cancers to treat, particularly when it comes to recurrent low-grade serous ovarian cancer (LGSOC) with KRAS mutations. On May 8, 2025, the FDA …

Read more